ATARA Biotherapeutics (ATRA) Misses Q2 EPS by 2c

ATARA Biotherapeutics (NASDAQ: ATRA) reported Q2 EPS of ($0.91), $0.02 worse than the analyst estimate of ($0.89). Revenue for the quarter came in at $3.87 million versus the consensus estimate of $3.84 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Assurant (AIZ) is Piper Sandler's Weekly Focus Idea
• Accenture downgraded by TD Cowen on AI concerns